EP1591446A4 — THIENOPYRIMIDINE COMPOUNDS AND USE
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2008-04-30 · 18y expired
What this patent protects
It is intended to provide a compound represented by the following general formula or its salt: wherein R1 represents C1-4 alkyl; R2 represents (1) a nitrogen-containing 5- to 7-membered heterocyclic group optionally having a substituent selected from among (1’) halogeno, (2’) hyd…
USPTO Abstract
It is intended to provide a compound represented by the following general formula or its salt: wherein R1 represents C1-4 alkyl; R2 represents (1) a nitrogen-containing 5- to 7-membered heterocyclic group optionally having a substituent selected from among (1’) halogeno, (2’) hydroxy, (3’) C1-4 alkyl and (4’) C1-4 alkoxy, (2) phenyl optionally having a substituent selected from among (1’) halogeno, (2’) C1-4 alkoxy-C1-4 alkyl, (3’) mono C1-4 alkyl-carbamoyl-C1-4 alkyl, (4’) C1-4 alkoxy and (5’) mono C1-4 alkylcarbamoyl-C1-4 alkoxy, etc.; R3 represents C1-4 alkyl; R4 represents C1-4 alkoxy, etc.; and n is an integer of from 1 to 4; as a thienopyrimidine compound having antagonism to gonadotropin-releasing hormone.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.